Nucor earnings beat by $0.08, revenue fell short of estimates
Joseph Michael Fitzgerald, the Executive Vice President and Group President of Cardiology at Boston Scientific Corp. (NYSE:BSX), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $152 billion, recently executed a significant transaction involving the company’s stock. According to InvestingPro data, the company maintains a GREAT financial health score and has delivered a strong 35% return over the past year. According to a recent filing, Fitzgerald sold 56,372 shares of Boston Scientific’s common stock on June 4, 2025. The shares were sold at a weighted average price of $102.88, resulting in a total transaction value of approximately $5.8 million. The transaction price aligns with the stock’s current trading level near its 52-week high of $107.17.
The sale was conducted under a pre-established Rule 10b5-1 trading plan, which was adopted on February 27, 2025. In addition to the sale, Fitzgerald also exercised stock options to acquire 56,372 shares of common stock at an exercise price of $26.15 per share, valued at approximately $1.47 million.
Following these transactions, Fitzgerald holds 178,342 shares directly, with an additional 5,234 shares indirectly held by his child. It is noted that Fitzgerald disclaims beneficial ownership of the shares held by his child.
In other recent news, Boston Scientific has confirmed its second quarter and full-year 2025 guidance for both reported and organic sales, as well as adjusted earnings per share (EPS), despite discontinuing its Acurate neo2 and Acurate Prime TAVR systems. This decision followed discussions with regulators that highlighted additional clinical and regulatory requirements, prompting the company to cease pursuing FDA approval for these products. The company reported that sales of Acurate systems in the EMEA region exceeded $200 million in 2024, showing double-digit growth, although there was no anticipated U.S. revenue due to uncertain commercial prospects. Analysts from Piper Sandler and TD Cowen have maintained their positive outlook on Boston Scientific, with price targets of $115.00, citing strong performance from products like Farapulse and Watchman. Citi analysts also reaffirmed a Buy rating with a $125.00 target, viewing the TAVR discontinuation as a strategic move that may benefit other companies like Edwards Lifesciences (NYSE:EW). Needham analysts echoed a similar sentiment, maintaining a $115.00 target and expressing optimism about the potential market impact of upcoming CHAMPION trial results for the Watchman device. The company’s strategic focus on expanding its market reach and capitalizing on new growth opportunities within the medical device sector remains evident.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.